Despite the extensive body of literature on rheumatoid arthritis (RA), the exact causes of the disease are not fully understood. Tumor necrosis factor alpha (TNF) is known to play a key role in the disease by stimulating catabolic processes and causing inflammation, and important elements of inflammation include changes in extracellular matrix compounds and their constituents, such as glycosaminoglycans.
Despite the extensive body of literature on rheumatoid arthritis (RA), the exact causes of the disease are not fully understood. Tumor necrosis factor alpha (TNF) is known to play a key role in the disease by stimulating catabolic processes and causing inflammation, and important elements of inflammation include changes in extracellular matrix compounds and their constituents, such as glycosaminoglycans (GAGs). GAGs are thought to play a role in RA pathogenesis; a recent study sought to describe the impact of anti-TNF agents on GAG levels in women patients with RA.
A total of 45 female patients who had an inadequate response to at least 2 disease-modifying anti-rheumatic drugs were recruited for the study; 22 received adalimumab, 19 received etanercept, and 4 received certolizumab pegol. All patients continued to take methotrexate and prednisone. Twenty age-matched volunteers were included as controls.
Sixteen patients were excluded from the study due to lack of efficacy, loss of response, withdrawal of consent, intolerance, or surgical procedures. The remaining 29 patients, all of whom responded well to biologic treatment, completed 15 months of therapy. A total of 38% achieved remission at month 9, and 80% achieved remission at month 15. The remaining patients had low disease activity.
In these patients, at 3 months, a statistically significant decrease in total GAG level was observed, and GAG levels continued to drop with therapy until levels matched those of the controls.
“To the best of our knowledge, this is the first study that reports an association between good clinical response to anti-TNF treatments and the plasma GAGs in RA patients,” write the authors, adding that the reduced GAG levels may be due to reduced enzymatic a nonenzymatic catabolic processes as a result of therapy.
The authors concluded that anti-TNF therapy in women patients with RA has a beneficial effect on metabolism of tissue GAGs, and that normalization of plasma levels of GAGs suggests improvement in the extracellular matrix remodeling balance.
Reference
Szeremeta A, Jura-Półtorak A, Koźma EM. Effects of a 15-month anti-TNF-a treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis. Arthritis Res Ther. 2018;20: 211. doi: 10.1186/s13075-018-1711-z.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.